Jonathan M. Hernandez, M.D.
Cholangiocarcinoma is a cancer of the bile ducts, a network of tubes that connect the liver, gallbladder and small intestine. One way to treat such cancer is to deliver drugs directly to the liver itself. A clinical trial led by Jonathan M. Hernandez, M.D., Investigator in the Surgical Oncology Program, is researching chemotherapy for liver-only cholangiocarcinoma (cancer that has occurred in the liver but has not spread elsewhere in the body). The trial will take place at the NIH Clinical Center in Bethesda, Maryland, and there is no cost for participation.
For more information, please contact Kate Smith at at (240) 858-3531 or kathleen.smith3@nih.gov
Clinicaltrials.gov identifier: NCT04891289
NCI Protocol ID: NCI000473
Official Title: A Randomized Phase II Study of Systemic Chemotherapy With or Without HAI FUDR/Dexamethasone in Patients With Unresectable Intrahepatic Cholangiocarcinoma
The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.
For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.
